Safinamide Mesylate Market

The Safinamide Mesylate market is projected to grow at a CAGR of 6.3% from 2025 to 2035, driven by increasing prevalence of Parkinson’s disease (PD), rising demand for adjunctive therapies in motor fluctuation management, and expanding clinical research into multi-mechanistic neuroprotective agents. Safinamide Mesylate is an orally active selective monoamine oxidase-B (MAO-B) inhibitor with additional mechanisms involving modulation of glutamate release and inhibition of sodium and calcium channels. This dual-action pharmacology not only enhances dopaminergic transmission but also offers potential benefits in reducing excitotoxicity and motor complications associated with long-term levodopa use.

Marketed under the brand name Xadago, Safinamide Mesylate is approved as an add-on therapy to levodopa/carbidopa in mid-to-late stage Parkinson’s patients experiencing “off” episodes. Clinical studies have demonstrated its efficacy in improving ON-time without troublesome dyskinesia, making it a valuable option in personalized PD management. Research is also ongoing into its utility for cognitive symptoms, neuropathic pain, and other neurodegenerative disorders. Increasing physician familiarity, patient preference for oral once-daily regimens, and improved symptom control with fewer side effects support market expansion.

Europe dominates the Safinamide Mesylate market, backed by early regulatory approvals, well-established Parkinson’s treatment protocols, and high diagnosis rates. North America follows closely, driven by rising awareness of PD, increased neurology consultations, and broader insurance coverage of adjunctive PD therapies. The Asia-Pacific region is expected to witness the fastest growth due to an aging population, improved access to neurologists, and growing healthcare infrastructure investments. Latin America and the Middle East & Africa regions are showing gradual adoption rates, spurred by improving diagnostic capabilities and broader access to movement disorder treatments.